Promising Nanomedicines of Shikonin for Cancer Therapy

Introduction

Malignant tumor is the leading cause of mortality worldwide.¹ Chemotherapy remains the primary therapy option for cancer patients to improve survival rate. Although encouraging progress has been made in clinical chemotherapy, disadvantages such as drug resistance and severe side effects are still witnessed, failing to exert a satisfactory effect. Thus, it is necessary to explore novel antitumor agents with excellent efficacy and reduced toxicity to overcome the above problem in cancer treatment.

Natural products extracted or optimized from nature have made great progress in anticancer therapy.^2–5 SHK ((±)-5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1,4-naphthoquinone) (Figure 1), a natural naphthoquinone separated from the Lithospermum erythrorhizon is a traditional Chinese Medicine used to treat several diseases, such as anaphylactoid purpura, burns, eczema, measles.⁶ Apart from botanical sources, the source of SHK involves chemical synthesis and biosynthesis, which may impel the clinical application of SHK.^7,8 Recently, studies have shown that SHK possesses a favorable therapeutic effect on cancer growth, development, and metastasis by regulating cancer cell proliferation, apoptosis, autophagy, necroptosis, and inducing immunogenic cell death (ICD) (Figure 2). In addition, SHK could regulate immunosuppressive tumor microenvironment through inhibiting glycolysis of tumor cells and repolarizing tumor-associated macrophages (TAMs). However, SHK is a hydrophobic natural molecule with unsatisfactory solubility, rapid intestinal absorption, obvious “first pass” effect, and rapid clearance, leading to low oral bioavailability.^9,10 For instance, SHK displays a half-life of 15.15 ± 1.41 h and Cmax of 0.94 ± 0.11 μg/ml in rats when administered intravenously.¹¹ In addition, SHK could induce serious skin sensitization, suicidal erythrocyte death, and potential toxicity in combination with other drugs through related metabolic enzymes.^12–16 Notably, due to these disadvantages, its further application is significantly restricted.

Figure 1 Chemical structure of shikonin.

Figure 2 Multiple molecular targets modulated by SHK in cancer therapy. Abbreviations: CCND1, Cyclin D1 gene; NF-κB, Nuclear factor kappa-B; Cdc25, Cell division cycle 25; HIF-1α, Hypoxia-inducible factor 1α; PKM2, Pyruvate kinase muscle isozyme M2; IMPDH2, Inosine-5’-monophosphate dehydrogenase 2; EGR1, Early growth response 1; ROS, Reactive oxygen species; PI3K, Phosphoinositide 3-kinase; AKT, Protein kinase B; Bcl-2, B-cell lymphoma-2; EGFR, Epithelial growth factor receptor; p-ERK, Phosphorylated extracellular regulated protein kinases; TrxR, Thioredoxin reductase; MAPK, Mitogen-activated protein kinase; ERK, Extracellular regulated protein kinases; ASK1, Apoptosis signal-regulating kinase 1; MKK3, Mitogen-activated Protein Kinase Kinase 3; Bax, Bcl-2-associated X protein; JNK, C-Jun-N-terminal kinase; MMP, Matrix metalloproteinase; CXCR4, Type IV C-X-C-motif chemokine receptor; SDF-1, Stromal cell–derived factor-1; VEGF, Vascular endothelial growth factor; STAT3, Signal transducer and activator of transcription 3; SRC, Proto-oncogene tyrosine-protein kinase Src; FAK, Focal adhesion kinase 1; DNMT1, Human DNA methyltransferase 1; RIP3, Receptor-interacting protein kinase 3; DAMPs, Damage associated molecular patterns; CSN5, COP9 signalosome 5.

Nanomedicine has attracted considerable attention over the past few decades, possessing advantages, such as prolonged circulation time, improved drug bioavailability, controllable drug release, enhanced therapeutic efficacy, and alleviated side effects. Additionally, increasing literature has demonstrated that developing nano drug delivery systems can improve bioavailability and strengthen the therapeutic efficacy of drugs without chemical modification. Encouragingly, Onivyde®, an irinotecan liposome injection approved by FDA, is harnessed to treat metastatic pancreatic cancer patients after gemcitabine therapy.¹⁷ Recent studies have demonstrated its encouraging anticancer activity in various malignancies such as pancreatic, esophago-gastric, and colorectal cancer.¹⁸ Various nanomedicines including Myocet®, Mepact®, Marqibo®, Doxil®, Abraxane®, Apealea®, and Vyxeos® were approved by FDA or EMA.^19–21 Therefore, nano drug delivery systems are effective approaches to improving the therapeutic efficiency of drugs. Given the shortcoming of SHK, enormous efforts have been devoted to developing various nano drug delivery systems such as liposomes, polymeric micelles, nanoparticles, nanogels, nanoemulsions, and chimeric advanced drug delivery nano systems (Chi-aDDnSs), for efficient delivery of SHK.

This review summarizes the anticancer activities and pharmacokinetics of SHK. Moreover, the latest updates of SHK nanomedicines in anticancer therapy are overviewed, with emphasis on long circulation, tumor targeting ability, tumor microenvironment responsive drug release, and nanosystem-mediated combination therapy. Such SHK nanomedicine exhibits improved bioavailability and outstanding therapeutic efficacy, which show great potential for ameliorating the limitations of SHK and facilitating clinical application.

Anti-Cancer Activities of SHK

SHK exerts a favorable therapeutic effect on breast, colon, lung, and other cancers via regulating cancer cell proliferation, apoptosis, metastasis, invasion, autophagy, necroptosis, and cellular immunity. The detailed roles of SHK in cancer treatment are shown in Table 1.

Table 1 The Anti-Cancer Activity of SHK in vitro

Inhibit Cell Proliferation

SHK exhibits a general anti-cancer effect on various cancer cells including lung adenocarcinoma (A549 cell), triple-negative breast cancer (MDA-MB-231 cell), pancreatic cancer (PANC-1 cell), and osteosarcoma (U2OS cell). Its cellular mechanisms might be arresting the cell cycle at the G2/M phase due to its P21 up-regulation.²² In addition, anti-cancer effects on MCF-7 and SK-BR-3 cells appear to be concerned about EGFR/p-ERK downregulation via Erα and GPER inhibition.²³ Moreover, SHK induces triple-negative breast cancer (TNBC) cell growth suppression is probably due to inhibiting IMPDH2 which is always involved in TNBC formation and progression.²⁴ One research indicates that SHK’s anti-proliferation activity in cancer cells (MCF-7, HeLa, K562, and tsFT210) was perhaps through inhibition of the Cdc25s.²⁵ Furthermore, SHK led to cell proliferation inhibition and cell-cycle arrest in hypoxia-induced human colon cancer cell lines by inhibiting the hypoxia-inducible factor-1α signaling pathway.²⁷

Induce Apoptosis

Apoptosis is a form of programmed cell death, but cancer cells avoid apoptosis through various mechanisms, including overexpressing or stabilizing antiapoptotic BCL-2 family proteins and inactivating apoptosis transcription factors.²⁸ Among them, the BCL-2 family can regulate apoptosis by controlling the permeability of the mitochondrial outer membrane.²⁹ A study has shown SHK induced-apoptosis occurs in human glioma cells through multiple pathways including inducing ROS production, GSH depletion, mitochondrial transmembrane potential disruption, p53 up-regulation, and PARP cleavage.²⁹ In addition, SHK can induce apoptosis of prostate cancer cells by induction of endoplasmic reticulum stress, and mitochondrial dysfunction.³⁰ Similarly, activation of endoplasmic reticulum stress also plays a role in inducing apoptosis of melanoma A375 cells.³¹ For gefitinib-resistant non-small cell lung cancer, SHK promoted apoptosis through EGFR degradation induced by ROS generation.⁴⁹ Furthermore, Kimura et al discovered SHK induced apoptosis via inhibiting the phosphorylation of IGF-1 receptors in myeloma cells.³²

Inhibit Cells Metastasis and Invasion

Persistent growth and metastasis are two basic characteristics of malignant tumors. Metastasis has been one of the challenges of cancer treatment and diagnosis.^33,34 Cancer metastasis involves a complex set of processes, such as cell adhesion to the extracellular matrix (ECM), cell invasion, angiogenesis, and lymphangiogenesis.³⁵ In one study, SHK inhibited invasion and metastasis of lung cancer A549 cells by inhibiting integrin β1 expression and ERK1/2 signaling pathway.³⁶ In addition, SHK suppressed colorectal cancer cell invasion through the ERK1/2/SIRT2 pathway.³⁷ The metastasis process needs the degradation of ECM components by proteolytic enzymes. MMPs, including MMP-2, 9, and 13, are the primary extracellular matrix-degrading enzymes.^38,39 SHK suppressed hepatocellular carcinoma cell, osteosarcoma, and prostate cancer cell migration by restraining the expression or activity of MMP.^40,41,154 Epithelial-to-mesenchymal transformation (EMT) is crucial to the establishment of metastasis in tumor progression.^42,43 Research suggests SHK could suppress triple-negative breast cancer cell metastasis through reversing EMT.⁴⁴

Induce Necroptosis, Autophagy, and Cellular Immunity

Necroptosis, a lytic, programmed cell death pathway involves deubiquitination of TNF signaling and RIP1, phosphorylation of RIP1 and RIP3, inactivation of Caspase 8, and phosphorylation of MLKL.⁴⁵ In docetaxel-resistant prostate cancer cells, SHK induced necroptosis by decreasing caspase 8 and increasing pRIP1 and pRIP3.⁴⁶ Similarly, SHK induced glioma cell necroptosis by ROS overproduction and promoting RIP1/RIP3 necrosome formation.⁴⁷ Wang et al identified that self-ubiquitination and degradation of cIAP1 and cIAP2 induced by SHK further led to a significantly decreased ubiquitination of RIP1, thus inhibiting MDA-MB-231 cell survival and accelerating necroptosis.⁴⁸ In addition, SHK induced a dominant necroptosis to avoid cancer resistance in MCF-7, HEK293 and their drug-resistant lines with overexpression of P-glycoprotein, Bcl-2, or Bcl-x.⁵⁰

Autophagy is a type II programmed cell death, and the regulation of autophagy can be an effective intervention strategy for cancer treatment.⁵¹ Enhanced autophagy is accompanied by SHK-stimulated RIPK1 and RIPK3-dependent necroptosis.⁵¹ Furthermore, SHK-induced autophagy directly contributes to DAMP upregulation which is the characteristic of ICD.^52–54 In a study, increased DAMPs expression and a highly mature state of dendritic cells indicated SHK induced a significant ICD effect.⁵⁵ Natural killer cells, a type of innate lymphocytes, play a role in controlling cancer progression. A study confirmed SHK enhanced NK cell proliferation and cytotoxicity of Caco-2 cells by regulating the expression of P-ERK1/2 and P-AKt.⁵⁶ PD-L1 is the primary ligand of programmed death 1 (PD-1). PD-L1 expression is an immune evasion mechanism exploited by various malignancies.^57–59 SHK promoted PD-L1 degradation and inhibited pancreatic cancer cells immune evasion by inhibiting the NF-κB/STAT3 and NF-κB /CSN5 signaling pathways.⁶⁰ TAM, a major part of the tumor microenvironment, is concerned about the progression of tumor. M2-TAMs exert anti-inflammatory and tumorigenic characteristics.⁶¹ SHK can reduce the production of lactate which is an important driving factor of TAM2 polarization, thus repolarizing M2-TAMs.⁶² Furthermore, SHK inhibits tumor growth in mice by suppressing PKM2-mediated aerobic glycolysis.^63,64

Pharmacokinetics of SHK

For many years, the in vivo process of SHK has been described mainly from rat animal models. The pharmacokinetic parameters in rat plasma were t_1/2β at 630.7 ± 124.9 min; C_max at 83.6 ± 8.8 ng/ml; T_max at 1.0 ± 0.0 min; V_d at 136.6 ± 10.5 l/kg after intravenous administration of a 5 mg/kg SHK.¹⁵⁶ The blood concentration of SHK was 0.48 μg/mL at 0.5 h after oral administration of a 25 g/kg SHK.¹⁵⁷ Interestingly, SHK was not detected at 10 h in the plasma When the intravenous dose was 1.5 mg/kg.¹⁰ Animal experiments showed that SHK had an obvious “first pass” effect in rats, with drug concentration highest in bile and liver.

Drug metabolism enzymes (DMEs) participate in the metabolism, and/or detoxification of exogenous substance. Most organs are provided with numerous DMEs, including phase I and phase II metabolic enzymes and phase III transporters.⁶⁵ SHK effectively upregulated protein expression of phase I enzymes, phase II enzymes, and phase III drug transporters.⁹ The metabolism of SHK was studied using rat liver microsomes cultured in vitro.⁶⁶ The results revealed that NADH increased the metabolic rate of SHK. And microsome concentration exhibits an obvious effect on metabolic rate. The hydroxylation of the naphthoquinone nucleus was the principal metabolic pathway of SHK, followed by generating glucuronide conjugates and excreting in the bile and urine. The bacterial transformation of SHK has been investigated using human intestinal bacteria. Bacteroides fragilis subsp. thetaotus could transform SHK extensively into ten metabolites.⁶⁷

When accessing the efficacy of drugs, safety issues must pay more attention to. SHK resulted in obvious animal weight loss when inhibited renal interstitial fibrosis as a glycolysis inhibitor.¹³ In addition, SHK could trigger serious skin sensitization at a low concentration.¹⁴ Moreover, SHK can promote Ca²⁺ entry and induce eryptosis, the suicidal erythrocyte death when treating human erythrocytes.¹⁵ A study reveals SHK might cause toxicity, especially drug-drug interactions based on an atypical inhibitory effect on CYP.¹⁶

In conclusion, SHK is a hydrophobic natural molecule with unsatisfactory solubility, rapid intestinal absorption, obvious “first pass” effect, and low oral bioavailability. In addition, existing literatures have revealed its adverse effects and non-selective toxicity. Thus, much more attention should be paid for effective application of SHK.

SHK Nanomedicines for Cancer Therapy

The existing literatures show that SHK has poor solubility and chemical stability in aqueous medium, which seriously limits its bioactivity in vivo. In addition, low oral bioavailability and the non-selective toxicity have restricted its application. Considering the promising advantages of nanomedicines to improve bioavailability, reduce adverse reaction and enhance the therapeutic efficacy of drugs, various SHK nanomedicines including liposomes, polymeric micelles, nanoparticles, nanoemulsions, nanogels, and chimeric advanced drug delivery nano systems have been developed to overcome the pharmacokinetic limitations of SHK (Figure 3). Briefly, the preparation method and physicochemical property of SHK nanomedicines are shown in Table 2.

Table 2 The Preparation and Physicochemical Property of SHK Nanomedicines

Figure 3 Various types of SHK-based nano-delivery systems for cancer therapy.

Liposomes

Liposomes are spherical vesicles consisted of lipid bilayers. Due to their unique structure, hydrophobic agents can be embedded in lipid bilayers and hydrophilic agents encapsulated in the central aqueous chamber.⁶⁸ Various liposomes such as conventional liposomes, long-circulating liposomes, actively targeted liposomes, and multifunctional liposomes have been reported to load SHK to improve the anticancer effect.

Conventional Liposomes

To meet urgent requirements for nutrient and oxygen supplies in tumors, the tumor blood vessels endothelial cell gap is large, the vascular wall smooth muscle layer is lacking, and the angiotensin receptor function is deficient. In addition, the tumor tissue lacks lymphatic vessels, prohibiting the return of lymph fluid. Thus macromolecular substances could easily pass through the vascular wall and accumulate in tumor tissues, and can not be carried away by lymphatic reflux, which is called enhanced permeability and retention (EPR) effect.⁶⁹ EPR effect has become the basis of many nanomedicines to achieve tumor targeting. Xia et al prepared SHK-loaded liposome (sh-L) via the thin-film hydration method.⁷⁰ The results showed that sh-L could reduce toxicity to endothelial cells, inhibit migration and trigger angiogenesis reduction. Tumor angiogenesis,⁷¹ one of the “hallmarks of cancer”, is critical to tumor growth, progression, and metastasis. The study provides implications for further research on the development of SHK nanomedicine based on inhibiting angiogenesis.

Long Circulating Liposomes

Despite the advantages, liposomes binding with serum proteins are easily caught by the reticuloendothelial system cells, failing to deliver drugs to target sites.⁷² To prolong circulation time and increase stability, long-circulating liposomes have been developed.⁷² One of the most significant ways to develop long-circulating liposomes is decorating them with a hydrophilic polymer, such as PEG.⁷³ Conventional and PEGylated SHK-loaded liposomes were prepared,⁷⁴ confirming that decorating PEG to the SHK-loaded liposomal surface decreased particle size (reduction varied between 17–45%), improved entrapment efficiency (increments varied from 13 to 18%), increased stability and resulted in more release (increase approximately 20–30%).

Actively Targeted Liposomes

Ligand-directed nanomedicines are expected to decrease side effects to normal cells, increase drug uptake at target sites and enhance anticancer efficacy, which is mainly accomplished by attaching ligands on the surface of drug carriers and then aggregating drugs around solid tumors by specific recognition and binding of ligand receptors on the tumor cell membrane.⁷⁵

RGD is an integrin recognition sequence which can bind to the ανβ3 receptor overexpressed on the angiogenic endothelium in various tumor.^76,77 RGD functionalized SHK-loaded liposome (RGD-SSLs-SHK) was developed.⁷⁸ RGD-SSLs-SHK showed superior cellular uptake via receptor-mediated endocytosis. Compared with SSLs-SHK, higher cytotoxicity to MDA-MB-231 cells was seen, without significant difference in that of MCF-7 cells, which might be due to the specific binding of RGD to ανβ3 receptors which are expressed on MDA-MB-231 cells rather than MCF-7 cells. CD44, a glycoprotein, is overexpressed in various tumor cell surfaces, including breast cancer.⁷⁹ HA, a principal CD44 binding molecule, exerts a preferable prospect in decorating nanocarriers. HA-modified SHK liposomes (HA-SHK-Lip) were developed for TNBC therapy.⁸⁰ Cellular uptake of HA-SHK-Lip in MDA-MB-231 cell was higher than SHK-Lip and free SHK, which is attributed to the CD44 receptor-mediated endocytosis. HA-SHK-Lip displayed more significant anticancer efficacy than SHK and SHK-Lip in vitro and vivo.

Multifunctional Liposomes

The complex tumor microenvironment prevents the drug from efficient delivery and brings great obstacles to tumor treatment.⁸¹ However, Based on tumor-specific pathological stimuli such as acidic microenvironments, redox milieu environments, and overexpressed enzymes, stimuli-responsive nanomedicines have shown excellent performance in realizing controlled drug release and tumor targeting.^82,83 Currently, the co-administration of two or more drugs can enhance anticancer efficacy by targeting different molecular pathways and reduce toxicity via decreasing individual drug doses.^84,85 Especially, co-administration of chemical drugs and immunomodulators is attracting researchers’ attention.⁸⁶ Due to the attractive characteristics mentioned above, the combination of stimulus-sensitive design, active targeting, co-administration, and cancer immunotherapy strategy has been reported to develop multifunctional SHK liposomes.

SHK and N-end rule inhibitor RFC11 were loaded into biotinylated liposomes.⁸⁷ SHK could induce necroptosis in various cancers via upregulating RIPK1/RIPK3/MLKL expression.^88,89 Interestingly, inhibiting the N-end rule pathway is conducive to increase the stability of RIPK1, sensitizing cells to necroptosis.^90–92 The cellular uptake was strikingly higher than the non-targeting counterparts in the CT26 cell line. In addition, the biotinylated liposome codelivery of RFC11 and SHK showed a synergistic antitumor effect in vitro and vivo via RIP1 and RIP3-dependent necroptosis. ICD could enhance the anticancer efficiency of certain drugs by integrating direct tumor cell killing with stimulated anticancer immunity.⁹³ But the dosage of SHK to trigger effective ICD may cause hepatoxicity. SHK at a low dose was combined with Anthracyclines to develop LipMS,¹⁵⁸ exhibiting a pH and GSH dual-sensitive release pattern mediated by copper. LipMS significantly inhibited melanoma growth and increased necrosis areas and apoptotic cells in comparison with single-encapsulated liposomes and the mixture. In addition, AST levels in all groups were higher than those in a normal saline group except LipMS1:1, indicating LipMS1:1 did not cause hepatotoxicity. Furthermore, LipMS1:1 reduced cardiotoxicity which is a well-known side effect of Anthracyclines.⁶ Further study showed LipMS triggered a significant ICD effect, immune memory, and did not form new tumors in the process. ICD is often accompanied with autophagy.⁹⁴ But autophagy could suppress immune response by robbing immune-related antigens.⁹⁵ Hydroxychloroquine (HCQ), an autophagy inhibitor, can increase SHK triggered immune-related antigens exposure in colon cancer. But the reduction of ATP results from autophagy suppression, weakening anticancer immune response. To solve the problem, LipHCQa was prepared by pH gradient with ATP wrapped in the aqueous phase.⁹⁶ The result showed the ATP in the aqueous phase of LipHCQa compensated the ATP reduction caused by autophagy suppression. Further, coadministration of LipSHK and LipHCQa at appropriate dosage achieved superior anticancer efficacy without suppressing the immune response.

Liposome is an efficient drug delivery system for SHK, with increased stability, long circulation, controlled release, and enhanced anticancer efficacy. Compared with passively targeted liposomes, actively targeted liposomes effectively enhance the cellular uptake of SHK and further improve the overall antitumor effect. Moreover, the co-administration of SHK and other drugs in liposomes amplified the anticancer effect and reduced the unfavorable effect.

Polymeric Micelles

Polymeric micelles are formed by amphiphilic polymers that self-assemble into nanostructures with hydrophilic shells and hydrophobic cores.^97,98 The shell protects the micelle from aggregation and precipitation and the core can hold hydrophobic drugs.

Su et al formulated SHK-loaded thermosensitive micelle (STN) for breast cancer therapy.⁹⁹ STN exhibited rapid SHK release (90%) at tumor sites with temperatures 3°C–5°C higher than normal tissue. The entrapment of SHK into the thermosensitive biodegradable micelles improved its accumulation and cytotoxicity in breast cancer in vitro and vivo. Apart from single-loaded micelles, mixed micelles (SHK/siIDO1-HMs) loading SHK and IDO-1 knockdown siRNA (siIDO1) were prepared to enhance immunotherapy for colon cancer¹⁶⁰ Cytotoxic T lymphocyte (CTL) activation triggered by ICD could induce tumor regression by IFN-γ secretion. But IFN-γ secretion can promote the generation of indoleamine 2, 3-dioxygenase-1 (IDO-1), which may be a chief culprit of the immunosuppressive tumor microenvironment (ITM).^100–102 Calreticulin (CRT) exposure, ATP secretion, extracellular significant release of HMGB1, and maturing rate of DCs all revealed SHK/siIDO1-HMs induced ICD notably. IDO-1, as an immunosuppressive enzyme, catalyzes the degradation of tryptophan to kynurenine.^103,104 Decreased IDO-1, and reduced kynurenine to tryptophan ratio in SHK/siIDO1-HMs group suggested SHK/siIDO1-HMs resolved the contradiction between ICD-triggered anticancer immunity and IDO-1 induced immunosuppression. In addition, the lowest tumor volume and weight, and prolonged survival in SHK/siIDO1-HMs group indicated SHK/siIDO1-HMs exerted outstanding anticancer effect in the CT26 tumor mouse model.

Mitochondria-targeted drug treatment is a potential strategy to overcome TNBC. SHK can not only induce apoptosis by inhibiting mitochondrial energy production, but also exhibit significant inhibitory effects on TNBC.^44,106,107 Triphenylphosphine (TPP) has been generally used as a specific ligand to mediate the mitochondrial targeting. SHK-loaded micelles prepared with TPP-PEG-Hyd-PCL/TPP-PEG-PCL/mPEG-PCL (ThTM/SHK) was incubated with FA-PEG-FA modified-red blood cells membranes to develop red blood cells membranes camouflaged micelle (ThTM/[email protected]) for mitochondria-targeted TNBC therapy.¹⁰⁵ Both FP-RBCm coating and TPP on micelles contribute to tumor lesion distribution, receptor-mediated cellular uptake, and electrostatic attraction-dependent mitochondrial targeting, thereby maximizing inhibitory effects on mitochondrial biosynthesis in TNBC cells. In vivo, ThTM/[email protected] suppressed TNBC tumor growth, lung metastasis, and mitochondrial biogenesis.

SHK-loaded polymeric micelles exhibited a controlled drug release pattern at target sites. Compared with single-loaded-polymeric micelles, dual-loaded-polymeric micelles resolved the contradiction between ICD-triggered anticancer immunity and IDO-1-induced immunosuppression. Moreover, “right-side-out” membrane-camouflaged SHK loaded-micelle significantly strengthened the antitumor efficacy.

Nanoparticles

Nanoparticles (NPs) have been developed with suitable size and surface characteristics to improve biodistribution and prolong circulation time.¹⁰⁸ Due to the attractive properties of NPs, a wide range of NPs including metallic nanoparticles, polymeric nanoparticles, lipid-polymer hybrid nanoparticles, biomimetic nanoparticles, and self-assembled nanoparticles have been reported to load SHK.

Metallic Nanoparticles

Silver nanoparticles (AgNPs), as a type of metallic nanoparticles,¹⁰⁹ have been broadly investigated due to their excellent properties such as easy to prepare and versatile functionalization sites.⁸⁴ In addition, AgNPs are considered to be an excellent synergistic agent.^110–113 SHK-loaded-silver nanoparticles (SHK-AgNPs) were prepared to achieve a synergistic effect for lung cancer.¹¹⁴ SHK-AgNPs were stable under physiological conditions and showed preferred distribution in lung. Furthermore, IC50 of SHK-AgNPs on A549 cells was lower than that of free SHK, silver nitrate, and phytomediated AgNPs, suggesting SHK and silver nanoparticles had a synergistic effect on inhibiting A549 cells.

Polymeric Nanoparticles

Polymeric nanoparticles have attracted numerous attention due to its fascinating properties such as drugs protection, controlled release, specific targeting.¹¹⁵ Poly (lactic-co-glycolic) acid (PLGA), a biodegradable copolymer of polylactic and polyglycolic acid approved by the FDA, shows great potential for drug delivery due to its advantages such as biodegradability, biocompatibility, and versatility.¹¹⁶

PEG and TEM1/endosialin-targeting antibody (Ab) modified PLGA NPs were synthesized to load SHK for ovarian cancer therapy.¹¹⁷ TEM1 is a protein mostly expressed on the surface of endothelial cells in newly formed blood vessels and cancer cells,¹¹⁸ making TEM1-specific targeting a promising approach for cancer therapy. Through active and specific targeting mediated by anti-TEM1 Ab/scFv, these NPs accumulated within the TME in which 80% SHK was released within 24–48 hours, indicating higher drug accumulation and continuous release of SHK in TME. Moreover, the NPs induced superior cytotoxic effects on ovarian cancer. Lf-modified PEG-PLGA NPs (Lf-NPs) were engineered to deliver SHK for glioma treatment.¹¹ Lactoferrin receptor (LfR) and the low-density lipoprotein receptor-related protein (LRP) are overexpressed on the blood-brain barrier cells and glioma cells surface, respectively.^119,120 Besides, LRP is a kind of lactoferrin specific receptor with excellent selectivity.^121,122 More than 60% of the drug in SHK/Lf-NPs experienced a continued release for more than 72 h. In Cytotoxicity assays, C6 cells were more responsive to Lf-modified SHK NPs. Further, higher brain tissues distribution and the brain/blood concentration ratios of SHK/Lf-NPs revealed that SHK/Lf-NPs possessed a significant brain targeting effect.

Lipid-Polymer Hybrid Nanoparticles

Lipid-polymer hybrid nanoparticles take the hydrophobic polymer as the core and the lipids and their hydrophilic corona as the shell, which integrate the advantages of polymeric nanoparticles and liposomes and overcome some of their shortcomings.

Nanoparticles co-loading SHK and PD-L1 knockdown siRNA (SHK/siR-NPs) were developed for cancer immunotherapy by easing PD-L1-regulated immune tolerance, inducing ICD, and repolarizing M2-TAMs.¹⁵⁹ By inhibiting tumor glucose metabolism, SHK can reduce the production of lactate which is an important driving factor of TAM2 polarization.⁶² Decreased PD-L1 protein, declined PD-L1 mRNA, higher IFN-γ secretion and lower cell viability suggested that SHK/siR-NPs inhibited CT26 cell via blocking PD-1/PD-L1 pathway. Obvious extracellular release of HMGB1, secretion of ATP, secretion of CTR, and marked maturation of DCs suggested that SHK/siR-NPs induced a significant ICD effect. Reduced M2-TAM markers and raised M1-TAM markers verified SHK/siR-NPs effectively repolarized M2-TAMs. Moreover, SHK/siR-NPs treated group showed the highest tumor distribution and tumor suppression in comparison with SHK-NPs, siRNA-NPs, and free SHK. Li et al constructed tumor growth factor β small interference RNA (siTGF-β) and SHK co-delivery nanoparticles for TNBC chemo-immunotherapy.¹²³ SHK-induced ICD exhibited a positive tumor inhibitory effect. Effective silencing of TGF- β by siTGF-β suppressed EMT, promoted CTL infiltration, inhibited regulatory T lymphocytes proliferation, and suppressed lung metastasis. Further, SHK/siTGF-β NPs exhibited a long-term immune memory to inhibit cancer recurrence.

ROS-sensitive prodrug nanomedicines are considered as promising platform for cancer therapy. But inefficient or incomplete prodrug activation caused by insufficient response or increasingly consumed ROS at the tumor site limits its efficiency.^124,125 Herein, a self-amplifying ROS-responsive prodrug NP ([email protected]) was synthesized.¹²⁶ DTC-PPB composed of two diethyldithiocarbamate (DTC) molecules binding by the ROS-sensitive phenylboronic ester bond. DTC or copper alone have no obvious cytotoxicity, but Cu (DTC)₂ is highly cytotoxic. DTC-PPB in response to higher ROS concentration in tumor sites, DTC released. DTC can chelate Cu²⁺ from the [email protected] to generate Cu (DTC)₂ and trigger SHK release. The released SHK can induce ROS generation, further promoting highly cytotoxic Cu (DTC)₂ formation. [email protected] showed enhanced drug accumulation in tumor site with minimal side effect to normal cells. Moreover, [email protected] exhibited excellent anticancer effect in vitro and in vivo.

Biomimetic Nanoparticles

An ideal drug delivery system is supposed to be relatively stable in blood circulation and release drugs as it arrives at the target sites. However, exogenous NPs are easy to be identified and eliminated by the immune system. Using endogenous components (eg, proteins, polysaccharides, and cell membranes) as camouflage to evade the immune system and enhance tumor cell–specific uptake is a promising strategy.¹²⁷

A mannosylated lactoferrin nanosystem (Man-LF NPs) co-delivering SHK and JQ1 was prepared to target colon cancer cells and TAM.⁶² JQ1 can effectively decrease PD-L1 expression in tumor cells when combined with other immune drugs.¹²⁸ Characteristics of cancer cells undergoing ICD, repolarization of TAM2, and PD-L1 downregulation were observed in the Man-LF NPs treated CT26 cells. In vivo biodistribution assay, higher tumor sites accumulation in Man-LF NPs group might be owing to MR and LPR-1 act as double targeting receptors for cancer cells and TAM. In addition, the highest inhibition rate was seen in Man-LF NPs treated immunocompetent CT26 tumor mouse model. Zhao et al fabricated albumin/lactoferrin hybrid biomimetic nanoparticles (BSA/LFNP) to co-deliver SHK and DSF to target glioma energy metabolism.¹²⁹ SHK, PKM2 inhibitor, can inhibit the glycolysis of tumor cells. Disulfiram (DSF) inhibits the ALDH1L1 enzyme in the 10-formyl-tetrahydrofolate-NADH-ATP metabolism axis, which can inhibit the supply of ATP and interfere with tumor energy metabolism. The results showed that BSA/LFNP possessed the advantages of BSA-mediated long circulation and LF-mediated blood-brain barrier penetration. DSF/SHK-loaded BSA/LFNP effectively inhibited GL261cell glycolysis and folic acid-NADH-ATP metabolic pathway, thus cutting off the energy supply of tumor cells. In addition, BSA/LFNP effectively suppressed tumor growth in the GL261 glioma model and increased the median survival time of mice.

In a study, SHK was loaded into hollow Prussian blue nanoparticles ([email protected]). PEI was decorated on the [email protected], which then adsorbed ICG. Finally, the RBC-4T1 hybrid membrane was camouflaged ICG/[email protected]@SHK to prepare HMGPHS NPs.¹³⁰ Decreased phagocytosis of macrophages in vitro and extended drug half-life in vivo suggested membrane coating has promoted immune evasion and prolonged the circulation time of HMGPHS NPs. Excellent homotypic targeting ability and anticancer activity in vitro and vivo may owe to the homing effect of 4T1 membrane and synergetic effect of photothermal therapy (PTT) and chemotherapy, respectively. Furthermore, SHK suppressed the 4T1 cells metastasis and reprogramed the TME via alleviating inflammation resulting from PTT.

Self-Assembled Nanoparticles

Most nano delivery carriers are usually exogenous materials without pharmacological activity. And biocompatibility, degradability, and toxicity of the materials need to be considered. The carrier-free nano-drug delivery system, a nanostructure assembled by the drug itself, with a superior drug-loading capability, and simple preparation method, has showed great potential in cancer therapy.¹⁶¹

A Fe(III)-SHK supramolecular nanomedicine (FSSNs) for tumor treatment through ferroptosis and necroptosis is designed.¹³¹ One mechanism by which tumor cells develop resistance to chemotherapy and radiotherapy is related to resistance to apoptosis.¹³² Designing novel medicines based on non-apoptotic cell death pathways is potential to achieve a long-term antitumor effect. The driving force of the preparation process is metal-polyphenol-coordinated interaction. SHK ethanol solution was added into FeCl₃·6H₂O deionized aqueous solution, stirring for an hour. After taken into tumor cells, FSSNs disassembled into Fe²⁺ and SHK under exposure to the high concentration of GSH in tumor sites. Due to the increase of Fe²⁺ level and the depletion of GSH, the LPO accumulated and the GPX₄ downregulated, which led to cancer cell ferroptosis. Moreover, the released SHK strengthened the intracellular oxidative stress degree, inducing tumor cell death through necroptosis.

Polymeric nanoparticles can easily manipulate carrier properties by selecting the type of polymer and the mode of the carrier assembly. Antibody-decorated and ligand-decorated PLGA NPs were engineered to encapsulate SHK, showing great tumor site targeting ability, high drug accumulation, and continuous release. Lipid-polymer hybrid nanoparticles can carry various drugs in a certain proportion, controlling the release of drugs and maintaining biocompatibility. DTC-PPB and Cu-SHK loaded lipid-polymer hybrid nanoparticles achieved Cu (DTC)₂ formation and SHK release by a self-amplifying positive feedback cycle via separating Cu²⁺ and DTC-PPB in nanostructure and lipid, respectively. Compared with liposomes and NPs, lipid-polymer hybrid nanoparticles possess higher stability and better biocompatibility, so they have a good prospect for gene delivery. SHK and siRNA play a synergistic effect in cancer immunotherapy via encapsulating in lipid-polymer hybrid nanoparticles. NPs are still facing challenges to regulate the in vivo fate of the drugs, biomimetic delivery may be a solution to this. Biomimetic SHK-loaded nanoparticles showed long circulation, enhanced immune evasion, excellent tumor-targeting ability, and superior antitumor efficacy. NPs assembled by SHK itself, with high drug loading capability and simple preparation method, exhibited antitumor effect via ferroptosis and necroptosis.

Nanoemulsions

Nanoemulsion (NE) is formed by water and oil phases, surfactants, and co-surfactants in appropriate proportions and different types of manufacture (low- or high-energy).^133–135 NE has great potential in pharmaceutics due to its attractive property including suitable size, improved dispersion of hydrophobic drug, enhanced absorption, and the potential to be modified with different ligands to target components present in tumor cells’ surfaces.

SHK not only can induce apoptosis through multiple pathways in human glioma cells¹³⁶ but also enhance the anti-glioma efficiency of certain chemotherapeutic agents such as docetaxel.¹³⁷ Herein, a T7/AS1411 modified and superparamagnetic Fe₃O₄ nanoparticles-embedded nanoemulsion encapsulated with DTX&SHK ([email protected]/AS1411/DTX&SHK-M) was developed for glioma treatment.¹³⁸ The highest drug distribution and glioma accumulation of DTX and SHK in [email protected]/AS1411/DTX&SHK-M group were seen compared with DTX+SHK, SHK&DTX-M, AS1411-DTX&SHK-M, and T7/AS1411-DTX&SHK-M. The luminescence (representing glioma) in [email protected]/AS1411/DTX&SHK-M- group was the lowest. Importantly, the bodyweight of mice treated with different nanoemulsions did not reduce obviously, indicating these nanoemulsions reduced systemic toxicity associated with chemotherapy drugs.

Nanogels

Nanogels are made from hydrogels with cross-linked polymer chains.^139,140 Nanogels are with good properties such as good biocompatibility, high drug loading capacity, customizable surface properties, and adjustable morphology.

STP-modified disulfide bond-crosslinked nanogel (STP-NG/SHK) was prepared to target osteosarcoma.¹⁴¹ The ratio of SHK released from nanogels in PBS without GSH at 72 h was lower than 17%, compared with 98.4% in the presence of GSH, attributing to disulfide bond in STP-NG/SHK responding to high concentrations of GSH in tumor sites. STP-NG/SHK inhibited osteosarcoma growth and pulmonary metastasis in vitro and vivo in an effective way. Moreover, STP-NG/SHK reduced myocardial toxicity triggered by SHK.

Chimeric Advanced Drug Delivery Nano Systems

Chimeric advanced drug delivery nano system is defined as a hybrid nanosystem due to the binding process of nanomaterials, which can provide advantages as drug carriers. The binding of liposomes and dendrimers in liposomal locked-in dendrimers has been reported, which have been considered as Chi-aDDnSs.¹⁴² Dendrimer molecules will bring new pharmacokinetics and possible pharmacological properties.

Chi-aDDnSs were prepared by combining three hyperbranched polymers with liposomes to load SHK.¹⁴³ LipoBs exhibited an impressive encapsulation efficiency compared with LipoAs because the non-complexed SHK can be encapsulated in the liposomal lipid bilayers in LipoBs rather than removed through centrifugation in LipoAs. Moreover, LipoBs experienced a continual 72h drug release, 95.51% for LipoB64–OH and 78.27% for LipoB-32-OH. No obvious increase was seen in the particle size under dark at 4°C for 5 days, suggesting LipoAs and LipoBs were stable under this condition. In another study, SHK-loaded liposomes, PEGylated SHK-loaded liposomes, SHK/hyperbranched polymers (HBP) complexes, conventional SHK-loaded chi-aDDnSs, and PEGylated SHK-loaded chi-aDDnSs were prepared.¹⁴⁴ The results showed SHK partly damaged the liposomes, yet a more fluid liposome structure is beneficial to encapsulate SHK into the bilayer. And SHK avoided HBPs entering liposomes, making an ordered DSPC bilayer developed due to the interactions between HBP and liposome. In addition, PEG improved the stability of SHK inside of the liposomes and HBPs promoted the overall stability of chi-aDDnSs. In conclusion, Chi-aDDnSs generate a high potential for delivering SHK due to their excellent capability to encapsulate drugs, alter drug release rate, and enhance overall stability.

Challenges and Perspective

For the attractive properties of SHK in cancer therapy, an increasing number of rational, functional, and efficient SHK nanomedicines have been developed. Compared with free SHK, SHK nanomedicines possess good stability, improved bioavailability (Table 3), prolonged circulation time, active targeting ability, more tumor-site drug accumulation, efficient cellular uptake, tumor stimuli-responsive drug release, and enhanced cancer cell-killing efficiency (Figure 4). In addition, good biocompatibility and security has been indicated in studies. Moreover, nano drug delivery systems-mediated synergistic anticancer therapy based on SHK and other drugs including therapeutic genes, chemotherapeutic agents, immunotherapeutic drugs, and photosensitizers (Figure 5), has exhibited outstanding therapeutic efficacy and reduced systematic side effects. Although great progress and promising clinical translation prospects of SHK nanomedicines (Table 4), there remain restrictions to realizing the clinical translation of SHK nanomedicines. Several vital issues need to be considered.

Table 3 Pharmacokinetics Properties and Bioavailability of Various SHK Nanomedicines

Table 4 The in vivo Application of SHK Nanomedicines for Cancer Therapy

Figure 4 A sketch of SHK nanomedicine to deliver drug into cancer cells: circulation in the blood, tumor accumulation, cellular internalization and intracellular drug release.

Figure 5 Nano drug delivery systems-mediated synergistic anticancer therapy based on SHK and other drugs including therapeutic genes, chemotherapeutic agents, immunotherapeutic drugs, and photosensitizers.

Quality Control

The structure, particle size, polydispersity, surface properties, and stability of nanomedicines exert great effects on the pharmacokinetic property and in vivo therapeutic efficacy. Thus, the preparation process should be precise and repeatable to ensure the consistent properties of the prepared SHK nanomedicines. Furthermore, it is particularly critical to balance the relationship between large-scale preparation and intelligent design to minimize complexity and optimize efficacy.

Biosafety

Biosafety is one of the main obstacles hindering the clinical translation of SHK nanomedicines. Organic solvents are regularly introduced into the preparation process of SHK nanomedicines. Therefore, researchers should attach more importance to the possible solvent residue. In addition, the biocompatibility of carrier materials is also an essential scientific problem. In the design of SHK nanomedicine, biocompatible, natural, and food-derived carrier materials, especially FDA-approved materials, would be ideal options. Moreover, an in-depth understanding of the in vivo metabolic process of the carrier materials is a necessary condition for good biocompatibility. In particular, nanomedicine will combine with the surrounding protein molecules to form a protein crown in the blood circulation, affecting the toxicological properties of the nanomedicine.¹⁴⁵ So, it is necessary to explore the biological mechanism of SHK nanomedicine protein crowns in the following study. Furthermore, long-term medication is the main treatment modality. But the long-term toxicity of SHK nanomedicines in vivo is neglected, which requires more attention.

Efficacy

The innovative design of a nano-drug delivery system to improve the efficacy of nanomedicine is an urgent problem to be solved. (1) Delivery efficiency. Nanomedicines are still facing challenges to pass through multiple biological barriers, including blood circulation, uptake by mononuclear phagocyte systems, intratumoral pressure, extracellular matrix, and cell membrane internalization. An ideal nanomedicine should possess stability transition (from being stable in the circulation, accumulation, penetration, and internalization steps to being disassembling in the release step), surface transition (from being neutral/pegylated/shielding in the circulation, accumulation, and penetration steps to being cationic/depegylated/exposin in the internalization step) and size transition properties (from being large in the circulation and accumulation steps to being small in the penetration step) to efficiently deliver drugs into cancer cells and exert high therapeutic efficacy with few side effects. A promising strategy might be integrating all needed nanoproperties into a SHK nanomedicine with stability, surface and size nanoproperty transitions to maximize the delivery efficiency.¹⁴⁶ Due to the heterogeneity of the EPR effect, SHK nanomedicines based on the EPR effect may fail to deliver drugs to tumor cells far from blood vessels, resulting in poor clinical efficacy and final chemotherapy failure. Comparatively, transcytosis, is a vesicle-mediated transport utilized by molecules to pass through biological barriers without depending on the EPR effect, providing a new probability in developing novel nanoparticles for in vivo drug delivery and tumor targeting.^147,148 Consequently, more attention should be paid to exploring transcytosis-mediated active delivery mechanism-based SHK nanomedicines. In addition, decorating nanomedicines with tumor penetrating peptides, camouflaging with cell membrane and modulating tumor extracellular matrix can improve the tumor targeting and penetration ability.^149–151 (2) Drug resistance. Drug resistance is one of the leading causes of cancer chemotherapy failure. As the drug resistance study is ignored in SHK nanomedicines, more effort should be devoted to providing sufficient anti-resistant activity studies. (3) Tumor metastasis. Tumor metastasis, a multi-stage malignant progression process, significantly affects the prognosis of patients.¹⁵² Compared with orthotopic tumors, metastatic tumors show completely different metabolic characteristics, providing an opportunity for the prevention and treatment of tumor metastasis. But the advantages of SHK in regulating tumor growth, development, and metastasis have not been fully exploited in SHK nanomedicine. Especially, little attention has been paid to the effect of SHK on tumor cell glycolysis. Through the rational design of SHK nanomedicine, the comprehensive regulation and control of tumor occurrence, development, and metastasis may be achieved. (4) Combination therapy. The integration of chemotherapy with other therapies, such as immunotherapy, radiotherapy, PTT, or photodynamic therapy, can play a significant antitumor role, which presents us with a vital developmental direction for SHK nanomedicines. (5) Administration sequence. Nano drug delivery system-mediated combination therapy of SHK and other agents exhibited excellent antitumor efficacy. However, combination therapy can also have a negative effect because of the interaction between drugs or cycle-specific differences. Thus, administration timing and sequence are required to be carefully investigated. (6) Interspecies discrepancy. SHK nanomedicines are proven to be effective in the preclinical animal model, but this fails to sufficiently predict the clinical outcome due to the interspecies discrepancy between patients and animals. The practical application of SHK nanomedicines requires a research partnership among clinicians, the pharmaceutical industry, and the academy. (7) Patient compliance. Intravenous injection is the general administration route with less patient compliance. Hence, the development of oral SHK nanomedicines with ideal therapeutic efficacy is ought to be focused on in further study.

Conclusion

As a potential anticancer drug, more and more rational, efficient and functional SHK nanomedicines have been designed. Compared with free SHK, SHK nanomedicines possess improved bioavailability, prolonged circulation time, active targeting ability, more tumor-site drug accumulation, controllable drug release, efficient cellular uptake, and enhanced cancer cell-killing efficiency. Most notably, SHK-involved combination therapy has exhibited outstanding therapeutic efficacy and reduced systematic side effects. It is our sincere hope that SHK-involved combination cancer therapy based on well-designed nanomedicines with easy quality control, good biosafety, and excellent delivery efficiency can contribute to cancer treatment in the near future.

Author Contributions

All authors have made major contributions to this work; contributed to drafting, revising, and critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 82204633); the China Postdoctoral Science Foundation (grant number 2021M700550); the National Natural Science Foundation of Sichuan Province (grant numbers 2022NSFSC0634, 2023NSFSC1782); Traditional Chinese Medicine Scientific Research Project of Sichuan Provincial Administration of traditional Chinese Medicine (grant number 2020JC0038); Talent training quality and Teaching Reform Project of higher Education in Sichuan Province (grant number JG2021-787); Sichuan traditional Chinese Medicine Health Industry Development and Rural Revitalization Research Center Project “Research on the practice path of Intelligent Management of traditional Chinese Medicine under the background of Rural Revitalization” (grant number DJKYB202215); and the talent research promotion plan of “Xinglin scholar” discipline in Chengdu University of Traditional Chinese Medicine (grant number BSH2021024).

Disclosure

The authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660

2. Bahrami A, Fereidouni M, Pirro M, et al. Modulation of regulatory T cells by natural products in cancer. Cancer Lett. 2019;459:72–85. doi:10.1016/j.canlet.2019.06.001

3. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002;2:143–148. doi:10.1038/nrc723

4. Mishra AP, Sharifi-Rad M, Shariati MA, et al. Bioactive compounds and health benefits of edible Rumex species-a review. Cell Mol Biol. 2018;64:27–34. doi:10.14715/cmb/2018.64.8.5

5. Mokbel K, Wazir U, Mokbel K. Chemoprevention of prostate cancer by natural agents: evidence from molecular and epidemiological studies. Anticancer Res. 2019;39:5231–5259. doi:10.21873/anticanres.13720

6. Guo C, He J, Song X, et al. Pharmacological properties and derivatives of shikonin—a review in recent years. Pharmacol Res. 2019;149:104463. doi:10.1016/j.phrs.2019.104463

7. Lu Q, Tang HL, Shao YQ, et al. A new facile synthesis of shikalkin. Chin Chem Lett. 2008;19:172–174. doi:10.1016/j.cclet.2007.11.031

8. Wu F-Y, Tang C-Y, Guo Y-M, et al. Transcriptome analysis explores genes related to shikonin biosynthesis in Lithospermeae plants and provides insights into Boraginales’ evolutionary history. Sci Rep. 2017;7:1–11. doi:10.1038/s41598-016-0028-x

9. Huang C-S, Chen H-W, Lin T-Y, et al. Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes. J Ethnopharmacol. 2018;216:18–25. doi:10.1016/j.jep.2018.01.026

10. Shao -Y-Y, Yin Y, Lian B-P, et al. Synthesis and biological evaluation of novel shikonin-benzo [b] furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site. Eur J Med Chem. 2020;190:112105. doi:10.1016/j.ejmech.2020.112105

11. Li H, Tong Y, Bai L, et al. Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma. Int J Biol Macromol. 2018;107:204–211. doi:10.1016/j.ijbiomac.2017.08.155

12. Sun Q, Gong T, Liu M, et al. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine. 2022;94:153805. doi:10.1016/j.phymed.2021.153805

13. Wei Q, Su J, Dong G, et al. Glycolysis inhibitors suppress renal interstitial fibrosis via divergent effects on fibroblasts and tubular cells. Am J Physiol Renal. 2019;316:F1162–F1172. doi:10.1152/ajprenal.00422.2018

14. Yamashita K, Miyazaki H, Shinoda S, et al. Assessment of the skin sensitizing potential of chemicals, contained in foods and/or cosmetic ingredients, using a modified local lymph node assay with an elicitation phase (LLNA: DAE) method. J Toxicol Sci. 2018;43:513–520. doi:10.2131/jts.43.513

15. Lupescu A, Bissinger R, Jilani K, et al. In vitro induction of erythrocyte phosphatidylserine translocation by the natural naphthoquinone shikonin. Toxins. 2014;6:1559–1574. doi:10.3390/toxins6051559

16. Tang S, Chen A, Zhou X, et al. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 2017;281:74–83. doi:10.1016/j.toxlet.2017.09.014

17. Adiseshaiah PP, Crist RM, Hook SS, et al. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13:750–765. doi:10.1038/nrclinonc.2016.119

18. Zhang H. Onivyde for the therapy of multiple solid tumors. OncoTargets Ther. 2016;9:3001. doi:10.2147/OTT.S105587

19. Barani M, Bilal M, Sabir F, et al. Nanotechnology in ovarian cancer: diagnosis and treatment. Life Sci. 2021;266:118914. doi:10.1016/j.lfs.2020.118914

20. Norouzi M, Amerian M, Amerian M, et al. Clinical applications of nanomedicine in cancer therapy. Drug Discov Today. 2020;25:107–125. doi:10.1016/j.drudis.2019.09.017

21. Seca C, Ferraresi A, Phadngam S, et al. Autophagy-dependent toxicity of amino-functionalized nanoparticles in ovarian cancer cells. J Mater Chem B. 2019;7:5376–5391. doi:10.1039/C9TB00935C

22. Wang F, Mayca Pozo F, Tian D, et al. Shikonin inhibits cancer through P21 upregulation and apoptosis induction. Front Pharmacol. 2020;11:861. doi:10.3389/fphar.2020.00861

23. Yang Y, Gao W, Tao S, et al. ER-mediated anti-tumor effects of shikonin on breast cancer. Eur J Pharmacol. 2019;863:172667. doi:10.1016/j.ejphar.2019.172667

24. Wang W, Wu Y, Chen S, et al. Shikonin is a novel and selective IMPDH2 inhibitor that target triple‐negative breast cancer. Phytother Res. 2021;35:463–476. doi:10.1002/ptr.6825

25. Zhang S, Gao Q, Li W, et al. Shikonin inhibits cancer cell cycling by targeting Cdc25s. BMC Cancer. 2019;19:1–9. doi:10.1186/s12885-018-5219-3

26. Wang, F, Mayca Pozo, F, Tian, D et al Shikonin inhibits cancer through P21 upregulation and apoptosis induction Frontiers in pharmacology 2020 11 861 doi:https://doi.org/10.3389/fphar.2020.00861

27. Li MY, Mi C, Wang KS, et al. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling. Chem Biol Interact. 2017;274:58–67. doi:10.1016/j.cbi.2017.06.029

28. Matsuura K, Canfield K, Feng W, et al. Metabolic regulation of apoptosis in cancer. Int Rev Cell Mol Biol. 2016;327:43–87.

29. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485–495. doi:10.1093/carcin/21.3.485

30. Gara RK, Srivastava VK, Duggal S, et al. Shikonin selectively induces apoptosis in human prostate cancer cells through the endoplasmic reticulum stress and mitochondrial apoptotic pathway. J Biomed Sci. 2015;22:1–12. doi:10.1186/s12929-015-0127-1

31. Liu Y, Kang X, Niu G, et al. Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways. Artif Cells Nanomed Biotechnol. 2019;47:626–635. doi:10.1080/21691401.2019.1575229

32. Kimura T, Nakazato T, Shimizu T, et al. Shikonin induces apoptosis by inhibiting phosphorylation of IGF-1 receptor in myeloma cells. Blood. 2004;104:4858. doi:10.1182/blood.V104.11.4858.4858

33. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978;38:2651–2660.

34. Veiseh O, Kievit FM, Ellenbogen RG, et al. Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Delivery Rev. 2011;63:582–596. doi:10.1016/j.addr.2011.01.010

35. Thompson EW, Price JT. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets. 2002;6:217–233. doi:10.1517/14728222.6.2.217

36. Wang H, Wu C, Wan S, et al. Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway. Toxicology. 2013;308:104–112. doi:10.1016/j.tox.2013.03.015

37. Zhang -L-L, Zhan L, Jin Y-D, et al. SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer. Eur J Pharmacol. 2017;797:1–8. doi:10.1016/j.ejphar.2017.01.008

38. Klein G, Vellenga E, Fraaije M, et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, eg acute leukemia. Crit Rev Oncol Hemat. 2004;50:87–100. doi:10.1016/j.critrevonc.2003.09.001

39. Simpson‐Haidaris P, Rybarczyk B. Tumors and fibrinogen: the role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci. 2001;936:406–425. doi:10.1111/j.1749-6632.2001.tb03525.x

40. Deng B, Qiu B. Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression. Tumor Biol. 2015;36:9311–9317. doi:10.1007/s13277-015-3662-1

41. Chen Y, Zheng L, Liu J, et al. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int Immunopharmacol. 2014;21:447–455. doi:10.1016/j.intimp.2014.05.026

42. Cannito S, Novo E, Di Bonzo LV, et al. Epithelial–mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 2010;12:1383–1430. doi:10.1089/ars.2009.2737

43. Jeong H, Ryu Y, An J, et al. Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype. Histopathology. 2012;60:E87–E95. doi:10.1111/j.1365-2559.2012.04195.x

44. Chen Y, Chen Z-Y, Chen L, et al. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling. Biochem Pharmacol. 2019;166:33–45. doi:10.1016/j.bcp.2019.05.001

45. Najafov A, Chen H, Yuan J. Necroptosis and cancer. Trends Cancer. 2017;3:294–301. doi:10.1016/j.trecan.2017.03.002

46. Markowitsch SD, Juetter KM, Schupp P, et al. Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis. Cancers. 2021;13:882. doi:10.3390/cancers13040882

47. Lu B, Gong X, Wang Z-Q, et al. Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation. Acta Pharmacol Sin. 2017;38:1543–1553. doi:10.1038/aps.2017.112

48. Wang A, Liu J, Yang Y, et al. Shikonin promotes ubiquitination and degradation of cIAP1/2-mediated apoptosis and necrosis in triple negative breast cancer cells. Chin Med. 2021;16:1–15. doi:10.1186/s13020-021-00426-1

49. Li X, Fan -X-X, Jiang Z-B, et al. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. Pharmacol Res. 2017;115:45–55. doi:10.1016/j.phrs.2016.11.011

50. Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 2007;6:1641–1649. doi:10.1158/1535-7163.MCT-06-0511

51. Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19:1–16. doi:10.1186/s12943-019-1085-0

52. Li Y, Wang L-X, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68:6889–6895. doi:10.1158/0008-5472.CAN-08-0161

53. Thorburn J, Horita H, Redzic J, et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2009;16:175–183. doi:10.1038/cdd.2008.143

54. Twitty CG, Jensen SM, Hu H-M, et al. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res. 2011;17:6467–6481. doi:10.1158/1078-0432.CCR-11-0812

55. Chen H-M, Wang P-H, Chen -S-S, et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immun. 2012;61:1989–2002. doi:10.1007/s00262-012-1258-9

56. Li Y, Lu H, Gu Y, et al. Enhancement of NK cells proliferation and function by Shikonin. Immunopharmacol Immunotoxicol. 2017;39:124–130. doi:10.1080/08923973.2017.1299174

57. Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–573. doi:10.1146/annurev-immunol-032414-112049

58. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. doi:10.1038/nm730

59. Feng M, Xiong G, Cao Z, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57–65. doi:10.1016/j.canlet.2017.08.006

60. Ruan Z, Liang M, Shang L, et al. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. Pancreatology. 2021;21:630–641. doi:10.1016/j.pan.2021.01.023

61. Yang Q, Guo N, Zhou Y, et al. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B. 2020;10:2156–2170. doi:10.1016/j.apsb.2020.04.004

62. Wang H, Tang Y, Fang Y, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett. 2019;19:2935–2944. doi:10.1021/acs.nanolett.9b00021

63. Chen J, Xie J, Jiang Z, et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297–4306. doi:10.1038/onc.2011.137

64. Zhao X, Zhu Y, Hu J, et al. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis. Sci Rep. 2018;8:1–8. doi:10.1038/s41598-017-17765-5

65. Xu C, Li CY-T, Kong NT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharmacal Res. 2005;28:249–268. doi:10.1007/BF02977789

66. Li H, Luo S, Zhou T. Studies on in vitro metabolism of shikonin. Phytother Res. 1999;13:236–238. doi:10.1002/(SICI)1099-1573(199905)13:3<236::AID-PTR417>3.0.CO;2-F

67. Meselhy MR, Kadota S, Tsubono K, et al. Biotransformation of shikonin by human intestinal bacteria. Tetrahedron. 1994;50:3081–3098. doi:10.1016/S0040-4020(01)81108-X

68. Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics. 2016;6:1336. doi:10.7150/thno.15464

69. Shi Y, Van der Meel R, Chen X, et al. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10:7921. doi:10.7150/thno.49577

70. Xia H, Tang C, Gui H, et al. Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo. Biosci Rep. 2013;33. doi:10.1042/BSR20120065

71. Pinto MP, Sotomayor P, Carrasco-Avino G, et al. Escaping antiangiogenic therapy: strategies employed by cancer cells. Int J Mol Sci. 2016;17:1489. doi:10.3390/ijms17091489

72. Ishihara A, Yamauchi M, Tsuchiya T, et al. A novel liposome surface modification agent that prolongs blood circulation and retains surface ligand reactivity. J Biomat Sci Polym E. 2012;23:2055–2068. doi:10.1163/092050611X605933

73. Rahim S, Ghamsari MS, Radiman S. Surface modification of titanium oxide nanocrystals with PEG. Sci Iran. 2012;19:948–953. doi:10.1016/j.scient.2012.03.009

74. Tsermentseli SK, Kontogiannopoulos KN, Papageorgiou VP, et al. Comparative study of PEGylated and conventional liposomes as carriers for shikonin. Fluids. 2018;3:36. doi:10.3390/fluids3020036

75. Yan W, Leung SS, To KK. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine. 2020;15:303–318. doi:10.2217/nnm-2019-0308

76. Cheng Y, Ji Y. RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur J Pharm Sci. 2019;128:8–17. doi:10.1016/j.ejps.2018.11.023

77. Mei L, Fu L, Shi K, et al. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int J Pharm. 2014;468:26–38. doi:10.1016/j.ijpharm.2014.04.008

78. Wen X, Li J, Cai D, et al. Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells. Molecules. 2018;23:268. doi:10.3390/molecules23020268

79. Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23:605–618. doi:10.3109/1061186X.2015.1052072

80. Meng L, Ren J, Liu Z, et al. Hyaluronic acid-coated shikonin liposomes for the treatment of triple-negative breast cancer via targeting tumor cells and amplification of oxidative stress. J Drug Delivery Sci Technol. 2022;70:103193. doi:10.1016/j.jddst.2022.103193

81. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. doi:10.1016/j.pharmthera.2020.107753

82. Kiran AVR, Kumari GK, Krishnamurthy PT, et al. Tumor microenvironment and nanotherapeutics: intruding the tumor fort. Biomater Sci. 2021;9:7667–7704. doi:10.1039/D1BM01127H

83. Lei Y, Hamada Y, Li J, et al. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. J Control Release. 2016;232:131–142. doi:10.1016/j.jconrel.2016.03.023

84. Li Y, Chang Y, Lian X, et al. Silver nanoparticles for enhanced cancer theranostics: in vitro and in vivo perspectives. J Biomed Nanotechnol. 2018;14:1515–1542. doi:10.1166/jbn.2018.2614

85. Larsson M, Huang W-T, Liu D-M, et al. Local co-administration of gene-silencing RNA and drugs in cancer therapy: state-of-the art and therapeutic potential. Cancer Treat Rev. 2017;55:128–135. doi:10.1016/j.ctrv.2017.03.004

86. Perciani CT, Liu LY, Wood L, et al. Enhancing immunity with nanomedicine: employing nanoparticles to harness the immune system. ACS nano. 2020;15:7–20. doi:10.1021/acsnano.0c08913

87. Agarwalla P, Banerjee R. N-end rule pathway inhibition assists colon tumor regression via necroptosis. Mol Ther Oncolytics. 2016;3:16020. doi:10.1038/mto.2016.20

88. Liu T, Sun X, Cao Z. Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression. OncoTargets Ther. 2019;12:2605. doi:10.2147/OTT.S200740

89. Shahsavari Z, Karami-Tehrani F, Salami S. Targeting cell necroptosis and apoptosis induced by shikonin via receptor interacting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7. Anti Cancer Agents Med Chem. 2018;18:245–254. doi:10.2174/1871520617666170919164055

90. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986;234:179–186. doi:10.1126/science.3018930

91. Piatkov KI, Brower CS, Varshavsky A. The N-end rule pathway counteracts cell death by destroying proapoptotic protein fragments. Proc Natl Acad Sci USA Early. 2012;109:E1839–E1847.

92. Tasaki T, Sriram SM, Park KS, et al. The N-end rule pathway. Annu Rev Biochem. 2012;81:261. doi:10.1146/annurev-biochem-051710-093308

93. Ahmed A, Tait SW. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006. doi:10.1002/1878-0261.12851

94. Gupta G, Borglum K, Chen H. Immunogenic cell death: a step ahead of autophagy in cancer therapy. J Cancer Immunol. 2021;3:47. doi:10.33696/cancerimmunol.3.041

95. White E, Lattime EC, Guo JY. Autophagy regulates stress responses, metabolism, and anticancer immunity. Trends Cancer. 2021;7:778–789. doi:10.1016/j.trecan.2021.05.003

96. Li J, Cai W, Yu J, et al. Autophagy inhibition recovers deficient ICD-based cancer immunotherapy. Biomaterials. 2022;287:121651. doi:10.1016/j.biomaterials.2022.121651

97. Cagel M, Tesan FC, Bernabeu E, et al. Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm. 2017;113:211–228. doi:10.1016/j.ejpb.2016.12.019

98. Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval. Adv Drug Delivery Rev. 2020;156:80–118.

99. Su Y, Huang N, Di Chen LZ, et al. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle. Int J Nanomed. 2017;12:4019. doi:10.2147/IJN.S132639

100. Adams JL, Smothers J, Srinivasan R, et al. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14:603–622. doi:10.1038/nrd4596

101. Mellor AL, Lemos H, Huang L. Indoleamine 2, 3-dioxygenase and tolerance: where are we now? Front Immunol. 2017;8:1360. doi:10.3389/fimmu.2017.01360

102. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74–80. doi:10.1038/nri2233

103. Crosignani S, Bingham P, Bottemanne P, et al. Discovery of a novel and selective indoleamine 2, 3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1 H-indol-3-yl) pyrrolidine-2, 5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate. J Med Chem. 2017;60:9617–9629. doi:10.1021/acs.jmedchem.7b00974

104. Zhao H, Sun P, Guo W, et al. Discovery of indoleamine 2, 3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product. Molecules. 2019;24:1059. doi:10.3390/molecules24061059

105. Peng J, Hu X, Fan S, et al. Inhibition of mitochondrial biosynthesis using a “right‐side‐out” membrane‐camouflaged micelle to facilitate the therapeutic effects of shikonin on triple‐negative breast cancer. Adv Healthcare Mate. 2022;11:2200742. doi:10.1002/adhm.202200742

106. Wiench B, Eichhorn T, Paulsen M, et al. Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. J Evid Based Integr Med. 2013;2012:126.

107. Qiu H-Y, Fu J-Y, Yang M-K, et al. Identification of new shikonin derivatives as STAT3 inhibitors. Biochem Pharmacol. 2017;146:74–86. doi:10.1016/j.bcp.2017.10.009

108. Aghebati‐Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235:1962–1972. doi:10.1002/jcp.29126

109. Desai N, Momin M, Khan T, et al. Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv. 2021;18:1261–1290. doi:10.1080/17425247.2021.1912008

110. AshaRani P, Low Kah Mun G, Hande MP, et al. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS nano. 2009;3:279–290. doi:10.1021/nn800596w

111. Jeong J-K, Gurunathan S, Kang M-H, et al. Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells. Sci Rep. 2016;6:1–13. doi:10.1038/srep21688

112. Mukherjee S, Chowdhury D, Kotcherlakota R, et al. Potential theranostics application of bio-synthesized silver nanoparticles (4-in-1 system). Theranostics. 2014;4:316. doi:10.7150/thno.7819

113. Sriram MI, Kanth SBM, Kalishwaralal K, et al. Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model. Int J Nanomed. 2010;5:753.

114. Fayez H, El‐Motaleb MA, Selim AA. Synergistic cytotoxicity of shikonin‐silver nanoparticles as an opportunity for lung cancer. J Labelled Compd Radiopharm. 2020;63:25–32. doi:10.1002/jlcr.3818

115. Crucho CI, Barros MT. Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater Sci Eng C. 2017;80:771–784. doi:10.1016/j.msec.2017.06.004

116. Anzar N, Mirza MA, Anwer K, et al. Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer. J Mol Liq. 2018;249:609–616. doi:10.1016/j.molliq.2017.11.081

117. Matthaiou E-I, Barar J, Sandaltzopoulos R, et al. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomed. 2014;9:1855.

118. Marty C, Langer-Machova Z, Sigrist S, et al. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 2006;235:298–308. doi:10.1016/j.canlet.2005.04.029

119. Elfinger M, Maucksch C, Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials. 2007;28:3448–3455. doi:10.1016/j.biomaterials.2007.04.011

120. Suzuki YA, Lönnerdal B. Baculovirus expression of mouse lactoferrin receptor and tissue distribution in the mouse. Biometals. 2004;17:301–309. doi:10.1023/B:BIOM.0000027709.42733.e4

121. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2. J Neurochem. 2008;106:1534–1544. doi:10.1111/j.1471-4159.2008.05492.x

122. Singh I, Swami R, Pooja D, et al. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting. J Drug Target. 2016;24:212–223. doi:10.3109/1061186X.2015.1068320

123. Li J, Zhao M, Liang W, et al. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy. J Control Release. 2022;342:308–320. doi:10.1016/j.jconrel.2022.01.015

124. Ye M, Han Y, Tang J, et al. A tumor‐specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers. Adv Mater. 2017;29:1702342. doi:10.1002/adma.201702342

125. Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccines Immunother. 2019;15:1111–1122. doi:10.1080/21645515.2019.1571892

126. Huang Z, Ding Y, Luo Y, et al. ROS-triggered cycle amplification effect: a prodrug activation nanoamplifier for tumor-specific therapy. Acta Biomater. 2022;152:367–379. doi:10.1016/j.actbio.2022.08.072

127. Asrorov AM, Gu Z, Li F, et al. Biomimetic camouflage delivery strategies for cancer therapy. Nanoscale. 2021;13:8693–8706. doi:10.1039/D1NR01127H

128. Zhu H, Bengsch F, Svoronos N, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16:2829–2837. doi:10.1016/j.celrep.2016.08.032

129. Zhao P, Qu J, Wu A, et al. Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination. Nano Today. 2022;44:101448. doi:10.1016/j.nantod.2022.101448

130. Liang J, Wang C, Fan J, et al. Hybrid membrane-camouflaged hollow Prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC. Mater Today Adv. 2022;14:100245. doi:10.1016/j.mtadv.2022.100245

131. Feng W, Shi W, Liu S, et al. Fe (III)‐shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis. Adv Healthcare Mate. 2022;11:2101926. doi:10.1002/adhm.202101926

132. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets. 2009;9:320–340. doi:10.2174/156800909788166600

133. Gorain B, Choudhury H, Nair AB, et al. Theranostic application of nanoemulsions in chemotherapy. Drug Discov Today. 2020;25:1174–1188. doi:10.1016/j.drudis.2020.04.013

134. Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol. 2011;2:626. doi:10.4236/jbnb.2011.225075

135. Sánchez-López E, Guerra M, Dias-Ferreira J, et al. Current applications of nanoemulsions in cancer therapeutics. Nanomaterials. 2019;9:821. doi:10.3390/nano9060821

136. Chen C-H, Lin M-L, Ong P-L, et al. Novel multiple apoptotic mechanism of shikonin in human glioma cells. Ann Surg Oncol. 2012;19:3097–3106. doi:10.1245/s10434-012-2324-4

137. Wang H, Zhu Z, Zhang G, et al. AS1411 aptamer/hyaluronic acid-bifunctionalized microemulsion co-loading shikonin and docetaxel for enhanced antiglioma therapy. J Pharm Sci. 2019;108:3684–3694. doi:10.1016/j.xphs.2019.08.017

138. Wang H, Chen W, Wu G, et al. A magnetic T7 peptide&AS1411 aptamer-modified microemulsion for triple glioma-targeted delivery of shikonin and docetaxel. J Pharm Sci. 2021;110:2946–2954. doi:10.1016/j.xphs.2021.03.018

139. Ferreira SA, Pereira P, Sampaio P, et al. Supramolecular assembled nanogel made of mannan. J Colloid Interface Sci. 2011;361:97–108. doi:10.1016/j.jcis.2011.05.020

140. Hashimoto Y, Mukai S, Sasaki Y, et al. Nanogel tectonics for tissue engineering: protein delivery systems with nanogel chaperones. Adv Healthcare Mate. 2018;7:1800729. doi:10.1002/adhm.201800729

141. Li S, Zhang T, Xu W, et al. Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics. 2018;8:1361. doi:10.7150/thno.18299

142. Purohit G, Sakthivel T, Florence AT. Interaction of cationic partial dendrimers with charged and neutral liposomes. Int J Pharm. 2001;214:71–76. doi:10.1016/S0378-5173(00)00635-9

143. Kontogiannopoulos KN, Assimopoulou AN, Hatziantoniou S, et al. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology. Int J Pharm. 2012;422:381–389. doi:10.1016/j.ijpharm.2011.09.031

144. Kontogiannopoulos KN, Dasargyri A, Ottaviani MF, et al. Advanced drug delivery nanosystems for Shikonin: a calorimetric and electron paramagnetic resonance study. Langmuir. 2018;34:9424–9434. doi:10.1021/acs.langmuir.8b00751

145. Cai R, Chen C. Protein Corona in vivo: dynamic complement proteins-mediated opsonization and immune modulation. Sci Bull. 2017;62:976–977. doi:10.1016/j.scib.2017.07.002

146. Sun Q, Zhou Z, Qiu N, et al. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater. 2017;29:1606628. doi:10.1002/adma.201606628

147. de Lázaro I, Mooney DJ. A nanoparticle’s pathway into tumours. Nat Mater. 2020;19:486–487. doi:10.1038/s41563-020-0669-9

148. Pandit S, Dutta D, Nie S. Active transcytosis and new opportunities for cancer nanomedicine. Nat Mater. 2020;19:478–480. doi:10.1038/s41563-020-0672-1

149. Zhang Q, Liu N, Wang J, et al. The recent advance of cell-penetrating and tumor-targeting peptides as drug delivery systems based on tumor microenvironment. Mol Biopharm. 2023;20:789–809. doi:10.1021/acs.molpharmaceut.2c00629

150. He X, Yang Y, Han Y, et al. Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment. Proc Natl Acad Sci. 2023;120(1):e2209260120. doi:10.1073/pnas.2209260120

151. Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release. 2015;220:600–607. doi:10.1016/j.jconrel.2015.07.019

152. Li HX, Wang SQ, Lian ZX, et al. Relationship between tumor infiltrating immune cells and tumor metastasis and its prognostic value in cancer. Cells. 2023;12(1):64. doi:10.3390/cells12010064

153. Shilnikova K, Piao MJ, Kang KA, et al. Shikonin induces mitochondria-mediated apoptosis and attenuates epithelial-mesenchymal transition in cisplatin-resistant human ovarian cancer cells. Oncol Lett. 2018;15:5417–5424. doi:10.3892/ol.2018.8065

154. Wei P-L, Tu -C-C, Chen C-H, et al. Shikonin suppresses the migratory ability of hepatocellular carcinoma cells. J Agric Food Chem. 2013;61:8191–8197. doi:10.1021/jf4009586

155. Wang Y, Hao F, Nan Y, et al. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis. Int J Biol Sci. 2018;14:1883. doi:10.7150/ijbs.27854

156. Huang S, Yu L and Shen P. (2010). Simultaneous Quantitative Analysis of Shikonin and Deoxyshikonin in Rat Plasma by Rapid LC–ESI–MS–MS. Chroma, 72(1–2), 63–69. 10.1365/s10337-010-1599-5

157. Li M, Chen X, Hu S, Wang R, Peng X and Bai X. (2018). Determination of blood concentrations of main active compounds in Zi-Cao-Cheng-Qi decoction and their total plasma protein binding rates based on hollow fiber liquid phase microextraction coupled with high performance liquid chromatography. Journal of Chromatography B, 1072 355–361. 10.1016/j.jchromb.2017.11.046

158. Li J, Zhou S, Yu J, et al. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release. 2021;335:306–319. doi:10.1016/j.jconrel.2021.05.040

159. Li J, Zhao M, Sun M, et al. Multifunctional nanoparticles boost cancer immunotherapy based on modulating the immunosuppressive tumor microenvironment. ACS Appl Mater Interfaces. 2020;12:50734–50747. doi:10.1021/acsami.0c14909

160. Li J, Zhao M, Xu Y, Hu X, Dai Y and Wang D. (2021). Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment. International Journal of Pharmaceutics, 597 120310 10.1016/j.ijpharm.2021.120310

161. Fu S, Li G, Zang W, Zhou X, Shi K and Zhai Y. (2022). Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy. Acta Pharmaceutica Sinica B, 12(1), 92–106. 10.1016/j.apsb.2021.08.012